|1.||Szechtman, Henry: 10 articles (02/2015 - 01/2002)|
|2.||France, Charles P: 10 articles (08/2014 - 03/2007)|
|3.||Baladi, Michelle G: 6 articles (12/2011 - 05/2009)|
|4.||Dvorkin-Gheva, Anna: 5 articles (02/2015 - 02/2013)|
|5.||Tucci, Mark C: 4 articles (02/2015 - 05/2013)|
|6.||Cheon, Paul: 3 articles (09/2014 - 05/2013)|
|7.||Taji, Leena: 3 articles (09/2014 - 05/2013)|
|8.||Eilam, David: 3 articles (06/2012 - 03/2005)|
|9.||Newman, Amy H: 3 articles (12/2011 - 01/2010)|
|10.||Koek, Wouter: 3 articles (12/2011 - 03/2007)|
08/01/2014 - "Quinpirole (0.0032-0.32 mg/kg) produced hypothermia and a low frequency of yawning. "
01/01/2010 - "The same antagonists were studied for their ability to attenuate quinpirole-induced yawning and hypothermia. "
09/01/1991 - "Quinpirole (0.125 to 1.0 mg/kg) was equiefficacious and equipotent in producing hypothermia in all 4 strains. "
08/01/2014 - "Eating high fat chow produced insulin resistance without affecting quinpirole-induced yawning or hypothermia. "
02/01/2012 - "Both quinpirole and 8-OH-DPAT led to faster induction of hypothermia. "
05/01/1995 - "In young adult monkeys, low quinpirole doses impaired performance of the PFC and fine motor tasks, while higher doses improved memory performance and induced dyskinesias and "hallucinatory-like" behaviors. "
09/01/2007 - "The D2 family agonist quinpirole, which induced mild dyskinesia on chronic treatment, did not produce BOLD changes in the striatum or motor cortex. "
04/01/1995 - "Combination treatment of quinpirole with SKF 82958 not only showed a tendency to augment the antiparkinsonian effects but also induced the marked hyperactivity and dyskinesias. "
04/01/1995 - "Both quinpirole and SKF 82958 alone improved the parkinsonism with a slight induction of the hyperactivity and dyskinesias. "
07/01/2014 - "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease. "
|3.||Bipolar Disorder (Mania)
10/01/2014 - "Given that the quinpirole-induced hyperactivity is an animal model of bipolar disorder, our results suggest individuals who have difficulties in recovery from circadian rhythm disruption may be vulnerable to bipolar disorder."
10/01/2014 - "To develop a screening method to detect individuals vulnerable to bipolar disorder, the authors observed the relationship between the recovery of the normal sleep-wake cycle after switching the light-dark (LD) cycle and quinpirole-induced hyperactivity in mice. "
03/01/2002 - "Quinpirole, a D2/D3 agonist, induces a biphasic locomotor response starting with inhibition and followed by excitation, resembling the oscillating nature of bipolar disorder. "
03/01/2002 - "A potential model for bipolar disorder, quinpirole-induced biphasic locomotion, was used for a preliminary evaluation of behavioral effects of oral anticonvulsant treatment. "
03/01/2002 - "Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder."
|4.||Body Weight (Weight, Body)
10/01/2011 - "Restricting access to standard or high-fat chow (maintaining or decreasing body weight) decreased or eliminated quinpirole-induced yawning; within 1 week of resuming free feeding, sensitivity to quinpirole was restored, although the descending limb of the dose-response curve was shifted leftward in rats eating high-fat chow. "
09/01/2006 - "Repeated treatment with quinpirole increased pouching behavior and body weight and disrupted PPI. "
01/01/2000 - "Thus, the observation that both stress schedules reduced body weight gain in a similar way, but only chronic mild stress reduced the sensitivity to the locomotor response to quinpirole, shows that this effect is not an artefact of body weight decrease."
09/01/2006 - "Female hamsters received two injections of quinpirole (1.5 mg/kg) or saline each week for 7 weeks, during which time pouching behavior and body weight were monitored. "
12/01/2011 - "Rats eating high fat chow gained more body weight than rats eating standard chow and, after 6 weeks of eating high fat chow, they were more sensitive to 8-OH-DPAT (0.01-0.1 mg/kg)-induced lower lip retraction and quinpirole (0.0032-0.32 mg/kg)-induced yawning. "
|5.||Amnesia (Dissociative Amnesia)
03/01/1995 - "Quinpirole was found to be more effective in attenuating amnesia than forgetfulness."
05/01/2001 - "Under the amnesia conditions, quinpirole reactivated the passive avoidance retrieval irrespective of the base initial behavior status (aggressive versus submissive). "
05/01/2001 - "The effect of quinpirole on the passive avoidance habit retention in male C57BL/6J mice with aggressive and submissive behavioral strategies was studied during the habit extinction and amnesia. "
05/01/2001 - "[Compensating and reactivating effects of quinpirole on extinction of conditioned response and amnesia in mice with alternative behavioral stereotypes]."
03/01/1989 - "[Effect of quinpirole on the retrieval of a memory trace in amnesia]."
|3.||2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)
|7.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|9.||SK&F 82958 (SKF 82958)